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Decamethylcyclopentasiloxane (D5) is a cyclic polydimethylsiloxane used in the synthesis of silicon-
based materials and as a component in consumer products. Male and female Fischer 344 rats were
exposed to D5 vapor (0, 10, 40, 160 ppm; whole-body inhalation) for 6 h/d, 5 d/wk, for up to 104 weeks.
Microscopic examination of tissues revealed test article effects at 160 ppm in the upper respiratory tract
(hyaline inclusions in males and females at 6, 12, and 24 months) and an increased incidence of uterine
endometrial adenocarcinoma at 24-months. The hyaline inclusions were considered a non-adverse tissue
response for lack of any other respiratory tract non-neoplastic or neoplastic changes. Uterine endome-
trial adenocarcinoma was not anticipated. Toxicity testing (mutagenicity/genotoxicity, acute, sub-acute
and sub-chronic descriptive toxicity) performed prior to the conduct of the chronic bioassay provided
no indication that the uterus was a potential target organ. The target organ and tumor type speciﬁcity
(adenocarcinoma is a common spontaneous tumor in the aged Fischer 344 rat) suggests the effect is
associated with estrous cycle alteration. A robust assessment of potential mode(s) of action responsible
for the uterine tumors and relevance to humans is addressed in a companion manuscript (Klaunig et al.,
2015).
© 2015 Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Polysiloxanes are high-performance synthetic materials of
commercial interest due to their unique chemical and physical
properties. As a polymer of “siloxane units,” two silicon atoms
covalently bound to one oxygen atom (-Si-O-Si-), polysiloxanes can
vary greatly in degree of polymerization and conﬁguration (linear,
cyclic, and three dimensional structures). The most basic and
abundant polysiloxanes are polydimethylsiloxanes, in which two
methyl groups are covalently bound to each silicon atom
(-(CH3)2SiO-).
Decamethylcyclopentasiloxane (D5) is a cyclic siloxane of ﬁve
siloxane units (Fig. 1). It is a volatile, colorless, and odorless liquid
with low water solubility (Table 1). D5 is used primarily in the
synthesis of larger siloxane polymers and also used in consumer
and industrial products. This range of uses leads to potential human
exposure, especially by the dermal and inhalation routes. A2200 West Salzburg Road
Jean).
s article under the CC BY-NC-ND licomprehensive testing program has been conducted utilizing pri-
marily the inhalation route. This was warranted based on 1) rele-
vance to human exposure, 2) the technical challenges associated
with spreading/evaporative losses following dermal application, 3)
D5's low dermal absorption potential (Jovanovic et al., 2008), and 4)
the similarity in kinetic behavior between the dermal and inhala-
tion routes (Sarangapani et al., 2003).
Studies, primarily in the rat, have included general descriptive
toxicity studies as well as reproductive and immune system toxi-
cology, disposition, and toxicokinetics of D5. These studies have
revealed that D5 is not extensively absorbed by oral, dermal, or
inhalation routes of exposure (Plotzke et al., 1994; Jovanovic et al.,
2008; McMahon et al., 2001; Reddy et al., 2007, 2008; Tobin et al.,
2008; Varaprath et al., 2003). Principal routes of elimination are by
exhalation of parent and urinary excretion of metabolites. Parti-
tioning into fat occurs readily; however, bioaccumulation has not
been demonstrated due to rapid exhalation elimination and
metabolism (Andersen et al., 2005, 2008). As is the case for
phenobarbital, D5 has been shown to induce liver enlargement,
hepatocellular hypertrophy/hyperplasia, and hepatic cytochrome
P450 induction (CYP2B1/2 primarily) in the rat (McKim et al., 1999;cense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Structure of decamethylcyclopentasiloxane.
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pregnane  receptor (PXR) and constitutive androstane receptor
(CAR) (Jean et al., 2006; Dow Corning Corporation, 2005a, 2005b).
These effects have been considered non-adverse and adaptive due
to the lack of apparent liver dysfunction and the reversibility seen
upon cessation of exposure. D5 was without adverse reproductive
and developmental effects in a two-generation reproductive study
in rats (Siddiqui et al., 2007). D5 was also without estrogenic,
androgenic or progestogenic activity in a series of in vitro and
in vivo assays (Quinn et al., 2007). D5 has not demonstrated
mutagenic/genotoxic potential in a battery of standardized testing
(Bacterial Reverse Mutation Assay, In Vitro Mammalian Cell Gene
Mutation Assay, In Vitro Mammalian Chromosomal Aberration
Assay, In Vitro Sister Chromatid Exchange Assay, and In Vivo
Micronucleus Assay).
This manuscript presents the results of the chronic toxicity/
oncogenicity study of D5 in the Fischer 344 rat (F344). Potential
modes of action that may be responsible for the unexpected uterine
neoplastic response are suggested, however a detailed evaluation
of speciﬁc modes of action are presented in a companion manu-
script (Klaunig et al., 2015).
2. Materials and methods
2.1. Test material
D5 was obtained from Dow Corning Corporation (Midland, MI).
Purity was determined prior to initiating exposures and at the start
and end of sampling of each drum. Purity was greater than 99.4% by
gas chromatography utilizing both thermal conductivity and mass
selective detection.
2.2. Test species and animal husbandry
Male and female CDF F344 rats were purchased from Charles
River Laboratories (Raleigh, NC) and were 6e8 weeks of age atTable 1
Physical and chemical properties of decamethylcyclopentasiloxane.
Property D5
Chemical Abstract Number 541-02-6
Molecular Weight (daltons) 371
Boiling Point 211 C
Melting Point 44 C
Saturated Vapor Concentration at 23 C 195 ppm (2.9 mg/L)
Water Solubility at 23 C 17 ppbinitiation of exposure. Animals were housed in Makrolon® type IV
cages at up to 5 animals/cage during the non-exposure periods and
transferred daily to suspended wire-mesh exposure cages (2/cage)
for the exposure. Food (Kliba 3433 rat maintenance diet, Provimi
Kliba AG, CH-4303 Kaiseraugst, Switzerland) and municipal water
were provided ad libitum with the following exceptions. Food and
water were withheld during the daily exposure period and food
was withheld the night prior to blood collections, and during urine
collection. Animals were housed in three rooms, one for controls,
one for 10 and 40 ppm groups, and one for the 160 ppm D5 group.
Recovery group animals were housed with controls during the
second year. A 12 h/12 h light (ﬂuorescent) and dark cycle was used.
Animal room temperature (target range of 22 ± 3 C and relative
humidity (target range of 40e70%) were continuously monitored.
Animals were observed at least twice daily for morbidity, mori-
bundity and mortality throughout the study.
The study complied with all applicable Animal Welfare Act
regulations (9 CFR, Parts 1, 2, and 3) and all experimental pro-
cedures were conducted in accordance with the American Associ-
ation for Laboratory Animal Science Policy on the Humane Care and
Use of Laboratory Animals (AALAC, 1991).
2.3. Inhalation exposure
Exposures were conducted ﬁve days/week for up to 24 months,
excluding holidays, in whole-body inhalation chambers. Daily ex-
posures consisted of a 6-h period at the target exposure concen-
tration sandwiched between chamber equilibration times during
which the chamber concentrations were increasing to 90% or
decreasing to 10% of the target. The average daily mean chamber
temperature (C)/relative humidity (%) for the duration of the study
were 24/48, 24/45, 25/45, and 25/44 for the control, 10, 40,160 ppm
exposure groups, respectively. Cage rack positions were rotated
weekly to limit positional effects. Adequate chamber oxygen con-
centration and test atmosphere homogeneity were demonstrated
periodically throughout the 24 month exposure period. Determi-
nation of test atmosphere concentration was performed by gas
chromatography with ﬂame ionization detection (GC/FID).
The maximum exposure concentration of 160 ppm D5 was
limited by the highest vapor concentration that could be reliably
generated without formation of appreciable aerosol or condensa-
tion. Intermediate exposure concentrations were selected based on
responses elicited in previous studies.
2.4. Study design
Rats were weight stratiﬁed and randomized into test groups.
Ninety-six rats of each sex were allocated to each exposure group;
control (air exposed), 10, 40, and 160 ppm D5. Within each of the 4
exposure groups were 4 subgroups; A (6-month exposure), B (12-
month exposure), C (12-month exposure/12-month recovery; Re-
covery), and D (24-month exposure).
Bodyweight datawere collected eachweek for the ﬁrst fourteen
weeks and then at least once every four weeks. Clinical observa-
tions were recorded each week for the ﬁrst fourteen weeks and
then at least once every two weeks.
At terminal sampling, a complete necropsywas performed on all
animals (except those in subgroup A (6-months exposure))
including gross and macroscopic evaluation and organ weight de-
terminations. Necropsy of animals in the 6-month exposure sub-
group included collection of liver, blood, and fat for tissue D5
determinations and a limited selection of organ weight de-
terminations (liver and pituitary). For each necropsy, tissues were
ﬁxed in 10% neutral buffered formalin, except for eyes which were
ﬁxed in Davidson's solution, processed routinely, and stained with
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trol and high-dose animals was typical of chronic toxicity and
oncogenicity study protocols (EPA, 1998). Additionally the liver,
lungs, kidneys, uterus, spleen, adrenals, nasal cavities, tissue
masses and gross lesions from all animals (except those in sub-
group A (6-months exposure)) were evaluated by the study
pathologist. Additional pathology reviews were performed to more
clearly detail the effects of exposure on the upper respiratory tract
and on selected hormone sensitive tissues (ovary, uterus, vagina,
mammary and pituitary glands). The nasal cavity was sectioned
following amodiﬁcation of the scheme reported by Young (1981) to
yield ﬁve levels. The ﬁrst section (level 1) was slightly more rostral
than that speciﬁed by Young for level 1, the second section (level 2)
represents tissue slightly rostral to the incisive papilla. A section cut
just caudal to the papilla was taken as level 3 in this study. Levels 4
and 5 in this study represent sections taken at the ﬁrst and second
palatal ridges consistent with levels 3 and 4 as deﬁned by Young.
Blood was collected from the orbital plexus from the Recovery
subgroup animals (fasted overnight) for clinical pathology at 3, 6,
and 12 months. Collections were performed on anesthetized ani-
mals (ether) prior to the daily exposure. Prothrombin time and
activated partial thromboplastin time was determined only at 12
months and from blood collected by cardiac puncture from sub-
group B (12-month exposure) animals. Urine was collected over-
night in a chilled (ice) reservoir at 3, 6, and 12 months.
To determine D5 levels tissue samples (plasma, fat, and liver)
from the 6-month exposure group were collected and extracted in
tetrahydrofuran. The dried (magnesium sulfate) extracts were
analyzed by GC/MS in accordance with the method of Varaprath
et al. (1998).
Prior to the ﬁrst exposure, ophthalmologic examinations were
performed following mydriatic treatment on all rats and again on a
portion of the animals of each exposure group after 12 and 24
months of exposure. Initial and periodic health screening found no
evidence of confounding infectious disease.
2.5. Statistical analysis
Body and organ weight and clinical pathology data were
analyzed by Dunnett's test if homogenous and by Steel test if non-
homogenous (p < 0.05). Survival analysis was performed utilizing a
Thomas, Breslow, and Gart program (Thomas et al., 1997), which
includes the KaplaneMeier product-limit procedure (Kaplan and
Meier, 1958) and assessment of treatment-related effects by the
Cox method (Cox, 1972). Statistical analysis of histomorphological
non-neoplastic ﬁndings utilized the Poly3 Test (Bailer and Portier,
1988) to identify signiﬁcant trend (p < 0.05) across the dose
groups as well as for pair-wise comparisons of individual dose
groups and control. Statistical analysis of neoplastic ﬁndings
involved a tiered approach. In the ﬁrst tier, Fisher's Exact Test
(Fisher, 1934, 1935; Iwin, 1935) was applied to assess differences
between control and individual dose groups (p < 0.05). Peto Mor-
tality Prevalence Test (Peto et al., 1980) was used to determine if
there was a signiﬁcant trend across the dose groups (p < 0.05). In
the second tier of testing the Poly3 test was applied to those
neoplastic ﬁndings for which the Peto Mortality Prevence Test
failed to detect a signiﬁcant trend (See companion manuscript for a
discussion of the statistical approach; Young and Morfeld, 2015).
3. Results
3.1. Exposure and tissue concentrations
The two year average mean daily exposure concentrations were
within 2.4% of the target values of 0 (control), 10, 40, and 160 ppmD5. Exposure yielded a dose-responsive increase in tissue concen-
trations assessed at the end of 6 months of exposure. Tissue con-
centrations of D5 for the liver, plasma, and fat (brown, peri-renal,
and abdominal) are provided in Table 2. Liver concentrations may
have been higher than was detected at the time of analysis due to
uncertaintywith cold storage stability of the tissue. Thus, the values
should only be used for relative comparisons. The toxicokinetic
interpretation of these data have been reported (Andersen et al.,
2008) and readers are referred to that publication for an in-depth
review.
3.2. Survival and clinical pathology
Mortality data are presented in Table 3. Two animals (one male,
one female) in the 12-month exposure group did not survive to the
scheduled necropsy. The female was a 10 ppm group animal that
died during blood collection procedures and the male was from the
160 ppm group and died as a consequence of malignant lymphoma.
These deaths were not attributed to D5 exposure. Mortality in the
24-month exposure group among all exposure levels ranged be-
tween 40 and 53% for males and 15e23% for females. The lack of a
doseeresponse suggests mortality was unaffected by the 24-
months of treatment. A much broader mortality range was seen
in the Recovery group (12 months exposure/12 months without
exposure). A range of 15e75% for males and 5e30% for females was
observed. The percent survival among the dose groups for males
was 60, 35, 85, and 25% for the control, 10, 40, and 160 ppm
exposure groups, respectively. The statistical analysis of these sur-
vival data for males was positive for trend (p < 0.05) and for the
pair-wise comparison (p < 0.05) of the 160 ppm exposure group to
control. However, the expressed mortality in these Recovery group
males was not considered treatment related due to the lack of a
similar effect in Recovery group females and in males and females
of the 24-month exposure group.
Clinical observations for all groups/subgroups were similar
across all exposure groups and not indicative of treatment-
related effects (Supplemental Data Table 1). Examination of the
eyes prior to initiation of the exposures identiﬁed corneal opacity
in 81% of all animals. Corneal opacity, common in F344 rats, was
present in all animals at the end of the ﬁrst and second year of
exposure. The incidence of clinically detectable masses was
similar between the 24-month exposure group (16.9%) and
the Recovery group (18.1%). Masses were found predominately
in the genital, axillary, abdominal, and ﬂank regions (Supple-
mental Data Table 2). Dose-response was lacking among expo-
sure levels.
Clinical pathology assessments (serum chemistry, hematology,
and urinalysis) resulted in a number of statistically identiﬁed dif-
ferences in exposed verses control animals (Supplemental Data
Table 3). However these differences were not considered to be of
toxicological relevance because they were of low magnitude, were
not dose responsive, and/or the effects were inconsistently present
among the time points (3, 6, or 12 months).
3.3. Body and organ weight
Body weight was generally equal to or slightly higher in the D5
exposed groups for both males and females across time and
exposure group/subgroups (Supplemental Data Table 4). The in-
crease in body weight occasionally showed a dose response effect
and at times the differences achieved statistical signiﬁcance.
Organ weight was determined for the pituitary and liver for the
6-month exposure group and brain, pituitary, heart, lungs, liver,
kidneys, adrenal glands, spleen, testes, epididymides, ovaries, and
uterus for animals in all other exposure groups (Supplemental Data
Table 2
Tissue levels of Decamethylcyclopentasiloxane.
Concentration of D5 (mg D5/g tissue)
Dose (ppm) Plasma Liver Fat
Abdominal Perirenal Brown
Male
0 0.12 [0.022] 0.14 [0.02] 0.205 [0.167] 0.092 [0.054] 0.177 [0.041]
10 0.19 [0.037] 1.09 [0.21] 2.09 [0.922] 2.04 [0.473] 0.979 [0.247]
40 0.47 [0.074] 5.23 [0.45] 5.92 [ 3.01] 9.37 [2.70] 7.42 [1.74]
160 2.20 [0.39] 24.2 [0.95] 23.0 [8.77] 54.5 [12.8] 32.0 [4.94]
Female
0 0.048 [0.039] 0.11 [0.02] 0.128 [0.046] 0.081 [0.03] 0.192 [0.136]
10 0.17 [0.024] 2.06 [0.19] 7.83 [2.82] 7.26 [0.64] 5.83 [0.562]
40 0.62 [0.032] 8.00 [0.91] 27.3 [ 9.06] 40.2 [10.5] 43 [18]
160 3.19 [0.758] 32.8 [2.97] 115 [42] 176 [58] 141 [23]
LOQ 0.027 0.09 0.013 0.023 0.023
Note: Values in brackets represent standard deviation of the mean D5 concentration. The limit of quantitation (LOQ) is also presented.
Table 3
Unscheduled mortality before the scheduled necropsy.
Sub-group Sex Group 1 0 ppm Group 2 10 ppm Group 3 40 ppm Group 4160 ppm
B Males 0/10 0/10 0/10 1/10
Females 0/10 1a/10 0/10 0/10
C Males 8/20 13/20 3/20 15/20
Females 6/20 2/20 6/20 1/20
D Males 26/60 29/60 24/60 32/60
Females 14/60 14/60 9/60 9/60
Sub-group B animals ¼ 1 year exposure.
Sub-group C animals ¼ 1 year exposure/1 year recovery.
Sub-group D animals ¼ 2 year exposure.
a Animal died during blood sampling.
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for the liver, brain, uterus, adrenal gland, and epididymides. In all
instances the organ weight changes appeared to occur without
relationship to dose. In a number of animals, the increased organ
weights were largely attributable to mononuclear cell leukemia
inﬁltration (lung, liver, spleen), adenoma of the pars distalis in the
pituitary, bursal dilation, follicular cysts or benign granulosa cell
tumor in the ovary, lipomatous tumor in the adrenal gland, and
stromal polyp or adenocarcinoma in the uterus.3.4. Macroscopic examination and histomorphology
Macroscopic examination was performed at necropsy for all
animals in all groups/subgroups. Macroscopic ﬁndings were
recorded for 94% of the 6-month exposure group animals, 50% of
the 12-month exposure group animals, and for all animals in the
Recovery group and the 24-month exposure group (Supplemental
Data Table 6). Differences between treated and control groups were
generally not statistically signiﬁcant, and none were considered
toxicologically relevant or treatment-related. Treatment related
histomorphological changes following exposure to D5 were limited
to the upper respiratory tract and the uterus.3.5. Upper respiratory tract effects
In both male and female rats the study pathologist's histopa-
thology assessment of the upper respiratory tract identiﬁed a
treatment-related increased incidence of hyaline inclusions in the
olfactory (primarily) and respiratory (occasionally) epithelium of
the nasal cavity. A second more focused assessment was performed
to better characterize the presence of hyaline inclusions within the
different tissue types and spatial location within the nasal cavity(Table 4). This review determined that the olfactory epitheliumwas
principally affected and with hyaline inclusions present in, but
without an apparent preference for, the dorsal and lateral meatus,
septum, and turbinates. Photomicrographs are provided in Fig. 2a
and b.
The hyaline inclusions were consistently present and at a
highest incidence in the 160 ppm exposure group for each of the
exposure periods (6, 12, and 24months). Females were consistently
more affected than males and nasal cavity levels 3 and 4 appear to
be more sensitive (Table 4). There was a clear lack of inﬂammatory
cell inﬁltration, tissue disorganization/degeneration, regeneration,
pre-neoplastic or neoplastic lesions at any time point or exposure
level.3.6. Uterine effects
The incidence of uterine endometrial adenocarcinoma (adeno-
carcinoma) in the two year exposure groups was 0/60, 1/60, 0/60,
and 5/60 in the control, 10, 40, and 160 ppm exposure groups,
respectively; the increase in incidence was statistically signiﬁcant
in the 160 ppm exposure group (Table 5). Adenocarcinoma was not
present in the 12-month exposure groups; however, adenocarci-
noma was present in the Recovery group animals. The incidence
among 20 animals per Recovery group included 1 in the control
group, 1 in the 10 ppm group, 0 in the 40 ppm group, and 2 in the
160 ppm group. The adenocarcinomas were not associated with
increases in precursor lesions such as uterine endometrial ade-
noma (none observed in this study) and focal glandular hyperplasia
(a single incidence in the 10 ppm recovery group). There was no
difference in incidence of cystic endometrial hyperplasia when the
uteri from control and 160 ppm groups were evaluated speciﬁcally
(see sensitive tissue review below) and no toxicologically relevant
Table 4
D5-Induced Incidence of Hyaline Inclusions in the upper Respiratory Tract.
D5 exposure group Proportion affected Tissue type Nasal level and Incidence(mean severity grade)
1 2 3 4 5
Males
6 months Control 1/6 olf e e 1(1) e e
res e e e e e
10 ppm 0/6 olf e e e e e
res e e e e e
40 ppm 0/6 olf e e e e e
res e e e e e
160 ppm 6/6 olf e e 2(1) 5(1) e
res e e e e e
12 months Control 0/10 olf e e e e e
res e e e e e
10 ppm 0/10 olf e e e e e
res e e e e e
40 ppm 1/10 olf e e e 1(1) e
res e e e e e
160 ppm 3/10 olf e 1(1) e 2(1) e
res e e e e e
24 Months Control 13/60 olf e 5(1) 5(1.2) 3(1) 6(1)
res e e e e e
10 ppm 6/60 olf e 1(1) 2(1) 1(2) 3(1)
res e e e e e
40 ppm 9/60 olf e 5(1) 2(1) 3(1.3) 3(1.3)
res e e e e e
160 ppm 43/60 olf e 12(1.3) 21(1.2) 32(1.3) 17(1.1)
res e e e e 3(1)
Recovery Control 1/20 olf e e e e 1(1)
res e e e e e
10 ppm 5/20 olf e 1(1) e 3(1) 2(1)
res e e e e e
40 ppm 6/20 olf e 2(1.5) 1(1) 1(1) 3(1)
res e e e e e
160 ppm 9/20 olf e e e 5(1) 6(1)
res e e e e e
Females
6 months Control 0/6 olf e e e e e
res e e e e e
10 ppm 0/6 olf e e e e e
res e e e e e
40 ppm 0/6 olf e e e e e
res e e e e e
160 ppm 4/6 olf e e 2(1) 1(1) e
res e 4(1) e e e
12 months Control 1/10 olf e e 1(2) e e
res e e e e e
10 ppm 1/10 olf e 1(1) 1(1) e e
res e e e e e
40 ppm 2/10 olf e 1(1) e 1(1) 1(1)
res e e e e e
160 ppm 9/10 olf e 3(1) 5/(1) 6(1.2) 3(1)
res e e e e e
24 Months Control 48/60 olf e 15(1.2) 32(1.6) 36(1.7) 13(1)
res e e e 2(1.5) 3(1.7)
10 ppm 41/60 olf e 16(1.3) 30(1.3) 33(1.4) 17(1.1)
res e e 2(1.) 2(1) 2(1)
40 ppm 48/60 olf e 14(1.1) 32(1.2) 40(1.4) 17(1.1)
res e e e 2(2) 4(1.3)
160 ppm 59/60 olf e 15(1.5) 53(1.5) 55(2) 27(1.6)
res e e e 10(2.3) 23(1.7)
Recovery Control 14/20 olf 1(1) 10(1.4) 10(1.6) 11(1.7) 7(1.1)
res 1(1) e e 1(1) e
10 ppm 15/20 olf e 4(1) 7(1.4) 11.(1.3) 6(1.2)
res e e e 1(1) e
40 ppm 12/20 olf e 1(1) 7(1.3) 11(1.3) 7(1.3)
res e e e e 1(1)
160 ppm 20/20 olf e 7(1) 19(1.7) 18(2.1) 12(1.5)
res e e e 3(2.3) 4(1.5)
Grading scale for Severity is as follows: 1. Minimal, 2. Slight, 3. Moderate, 4. Marked, 5. Severe.
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broadly.
Histomorphologically, the adenocarcinomas were characterizedby malignant epithelial tissue consisting of glands, cords, or sheets
of cells featuring cytological atypia, often characterized by nuclear
pleiomorphism, vesiculization, and prominent nucleoli (Fig. 3).
Fig. 2. A Nasal cavity level 4 (160 ppm female) according to Young (1985). Note diffuse
distribution of eosinophilic inclusions at a moderate degree in the olfactory mucosa of
the dorsal meatus and turbinates. Hematoxylin and eosin, lens 10. B. Nasal cavity
level 4 (160 ppm female) according to Young (1985). Higher magniﬁcation. The
morphology and distribution of eosinophilic inclusions is not different from sponta-
neously occurring changes. Note: the olfactory mucosa is intact. No further degener-
ative, inﬂammatory or hyperplastic lesion is visible. The cilia on the surface are
persevered. The submucosa is fully intact. Also there is no inﬂammatory or degener-
ative lesion notable. Bowmans glands and nerve ﬁbers are normal. Hematoxylin and
eosin, lens 40.
Fig. 3. Uterine endometrial adenocarcinoma showing pleiomorphic epithelial cells
with vesicular nuclei and prominent nucleoli. This animal was exposed to 160 ppm D5
for 24 months. Scale bar is 50 mm.
P.A. Jean et al. / Regulatory Toxicology and Pharmacology 74 (2016) S57eS66S62Bizarre mitotic ﬁgures, evidence of necrosis/apoptosis, and cellular
debris were also seen (Fig. 4). Stroma was often scanty, ﬁbrotic, or
contained a mononuclear inﬁltrate. Many of the tumors replaced
the endometrial cavity or uterus or invadedmyometrium, serosa, or
neighboring fat (Fig. 5).
The adenocarcinomas present in the 160 ppm exposure group
were indistinguishable from the one in the Recovery control group.
A histomorphological comparison was also performed with 110
spontaneous adenocarcinomas from the untreated control groupsTable 5
Uterine effects associated with chronic D5 vapor inhalation Exposure in the Rat.
Exposure concentration (ppm D5) 2-Year Exposure group (subgroup D)
Cystic endometrial Hyperplasiaa Endometrial ad
0 9/60 (1.8) 0/60
10 __ 1/60
40 __ 0/60
160 9/60 (2.4) 5/60
a Incidence (median severity grade) per sensitive tissue review pathologist (completeof F344 rats from 107 NTP 2-year chronic bioassays (Klaunig et al.,
2015). The review pathologist concluded that the histomorphology
of the adenocarcinomas from the D5 chronic bioassay (treated and
control groups) was not different from those present in the NTP
bioassay control group animals.
3.7. Other neoplastic ﬁndings
Exposure to 160 ppm D5 vapor for 24-months was associated
with a statistically signiﬁcant decrease in incidence (p < 0.05) of
mammary gland ﬁbroadenoma in females and thyroid C-cell ade-
noma and combined C-cell adenocarcinoma in males (Table 6).
These neoplasic lesions are common in the F344 rat (Kuroiwa et al.,
2013; Chandra and Frith, 1992; Haseman et al., 1998).
3.8. Detailed histomorphological review of the ovarian, vaginal and
uterine lesions
The increased incidence of uterine endometrial adenocarcinoma
in the high dose group was unexpected, and in an effort to enhance
our understanding of the circumstances surrounding its appear-
ance a detailed histomorphological evaluation of the uterus,
ovaries, mammary gland, pituitary and vagina was conducted. The
objective was to assess speciﬁc non-neoplastic histomorphological
features of these tissues to determine the potential hormonal in-
ﬂuences relative to exposure to D5. Tissues from the control and
160 ppm exposure groups were evaluated for the 6-, 12-, and 24-1-Year Exposure/Recovery group (subgroup C)
enocarcinoma Cystic endometrial Hyperplasiaa Endometrial adenocarcinoma
0/20 1/20
__ 1/20
__ 0/20
2/20 (1) 2/20
evalution of control and high dose only).
Fig. 4. Uterine endometrial adenocarcinoma show pleiomorphic endothelial cells,
minimal stroma, and abnormal mitotic ﬁgures (arrows). This animal was exposed to
160 ppm D5 for 24 months. Scale bar is 50 mm.
Fig. 5. Uterine endometrial adenocarcinoma has replaced much of the normal uterus
and extends to neighboring adipose tissue (arrows). This animal was exposed to
160 ppm D5 for 24 months. Scale bar is 1 mm.
Table 6
Neoplastic lesions demonstrating a treatment-related Reduced Incidence.a
Tissue Finding Sex
Mammary Gland Fibroadenoma Female
Thyroid Gland C-Cell Adenoma Male
Thyroid Gland C-Cell Adenoma þ Carcinoma Male
a Neoplasia incidence for animals in the 24-month treatment groups. Values reﬂect th
b Signiﬁcant negative Peto trend test (p < 0.05).
c Signiﬁcant negative Fisher's Exact test (p < 0.05).
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The non-neoplastic histomorphological features of the mam-
mary and pituitary glands were typical for the age and strain of rat
and lacked any obvious indication of a D5-related treatment effect.
The assessment of the uterus, ovaries, and vaginal tissue suggested
the potential for alteration of estrous cyclicity in the D5 exposed
animals (Table 7). Following 6-months of exposure, the number of
normally cycling rats and estrogenic verses progestogenic uterine
estrous stages were similar in control vs treated groups. After 12-
months of exposure, 6 of the 10 control and 6 of the ten 160 ppm
group females were considered to be cycling abnormally. However
there was a marked difference in uterine estrous phase between
the two groups. The uteri of 8 of 10 control group animals appeared
to be in an estrogenic estrous stage. In contrast, only 2 of ten
160 ppm group animals were in an estrogenic estrous stage, the
remaining animals were in a progestogenic state (diestrus I or II).
No differences in cyclicity or the uterine estrous phase was
apparent in the 24-month exposure control vs treated groups. Only
8 of 60 animals in each group were showing signs suggesting
normal cycling. The uteri in both groups were predominately
demonstrating a progestogenic state (49 of 60 controls and 50 of
sixty 160 ppm group animals). The recovery group animals
demonstrated a difference in the proportion of “normally cycling”
animals (3/20 controls vs. 7/20 in the 160 ppm group) and a dif-
ference in the proportion of animals in the uterine progestogenic
phase (15/20 controls vs. 20/20 in the 160 ppm group).
4. Discussion
Vapor inhalation exposure of F344 rats to D5 for up to 2 years
was well tolerated. There were no toxicologically relevant changes
in body weight, appearance, or behavior suggestive of systemic
toxicity. A reversible increase in liver weight has been reported
following D5 vapor inhalation exposure of rats in sub-chronic
toxicity studies (Burns-Naas et al., 1998a, 1998b; McKim et al.,
1999). Hepatocellular hyperplasia and centrilobular hypertrophy
were demonstrated after the ﬁrst week of vapor inhalation expo-
sure of female F344 rats to D5 but these effects proved transient in
that they were not present after 2 or 4 weeks of exposure (Jean,
2005). D5 has also been shown to be a functional ligand for CAR
and PXR in an in vitro reporter gene assay (Jean et al., 2006; Dow
Corning Corporation, 2005a, 2005b) and, consistent with this
property, to induce hepatic CYP 2B1/2 and CYP3A1 in vivo (McKim
et al., 1999; Zhang et al., 2000). In total these effects likely represent
an adaptive response purposed with increasing hepatic metabolic
capacity in an effort to metabolize and remove D5.
The phenobarbital-like liver effect of D5 pointed to a potential
for chronic exposure to yield liver tumors in the current rodent
bioassay. However, as was observed in the current study, exposure
to D5 vapor for 6, 12, and 24months was without notable effects on
liver weight or histomorphology. There were no preneoplastic or
neoplastic changes in the liver of D5 exposed rats at any of the timeVapor concentration of D5
0 ppm 10 ppm 40 ppm 160 ppm
8 (60)b 7 (60) 7 (60) 2 (60)c
9 (60)b 6 (32) 1 (25) 2 (60)c
10 (60)b 7 (32) 3 (25) 3 (60)c
e incidence observed (total number of animals evaluated).
Table 7
Histomorphological features in Uterine, Vaginal, and Ovarian Tissue Following Inhalation Exposure to Decamethylcyclopentasiloxane.
Tissue/Diagnosis 6-Month Incidence 12-Month Incidence 24-Month Incidence 12/12 Recovery
incidence
Control D5 Control D5 Control D5 Control D5
Ovary (No. Examined) 6 6 10 10 60 60 20 20
Old Corpora Lutea (CL) 6 6 10 10 52 50 17 20
Eosinophilic CL 6 5 7 7 34 36 15 20
Basophillic incomplete CL 1 3 3 3 5 2 3 5
Basophillic complete CL 4 3 2 6 22 18 13 5
Basophillic CL w/luteolysis 4 1 5 5 15 9 3 4
Antral Follicles [total] 5[18] 4[14] 5[7] 6[13] 14[18] 15[27] 6[6] 10[18]
Atretic Follicles, antral size[total] 6[36] 6[31] 10[56] 10[65] 55[252] 58[274] 19[86] 19[90]
Uterus (No. Examined) 6 6 10 10 60 60 20 20
Proestrus 4 2 5 0 7 6 3 0
Estrus 1 3 3 2 4 3 2 0
Diestrus I 0 1 1 3 7 0 4 5
Diestrus II 1 0 1 5 42 50 9 15
Vagina (No. Examined) 6 6 10 10 60 60 17 20
Epithelial Thickness
mimimal 0 0 0 2 28 31 7 9
mild 1 1 4 7 21 21 7 9
moderate 5 5 6 1 11 7 3 2
Corniﬁcation
minimal 1 1 4 0 8 5 1 0
mild 2 2 3 2 4 2 0 0
Sloughed Corniﬁcation
minimal 1 3 2 0 10 4 5 1
mild 1 0 2 1 2 0 0 2
Muciﬁcation
minimal 0 0 2 1 8 10 3 5
mild 3 0 3 3 19 21 4 5
moderate 0 1 0 0 12 13 1 4
severe 0 0 0 0 4 3 2 1
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that the hepatic responses observed in the shorter term studies
were representative of adaptive responses.
This study has also demonstrated a modest response to D5 va-
por exposurewithin the upper respiratory tract. Hyaline inclusions,
though present in the control group and demonstrating an
increased incidence with age, occurred at a higher incidence in the
160 ppm exposure levels at each of the time points including the
recovery group animals. Hyaline inclusions (also referred to as
eosinophilic globules, eosinophilic droplets, and epithelial hyali-
nosis) in the nasal cavities are characterized as an “… accumulation
of brightly eosinophilic cytoplasmic inclusions in sustentacular
cells of olfactory epithelium, respiratory epithelial cells, and
epithelial cells of the nasal seromucous glands …” (Renne et al.,
2009), are believed to be proteinaceous in nature. The inclusions
are commonly observed in laboratory animal studies involving
inhalation exposure; however, they are not exclusive to this expo-
sure route. The mechanism(s) involved in their emergence and
persistence is not understood. Though they are often observed
following inhalation exposure to noxious substances causing
various degrees of nasal tissue injury, it is yet uncertain if they
represent a non-speciﬁc adaptive response, a speciﬁc response to
tissue injury, or an adverse effect in and of itself. The clear lack of
nasal tissue injury (degeneration, necrosis, inﬂammatory inﬁltrate,
dysplasia, and/or neoplasia) following repeated inhalation expo-
sure to D5 vapor for 6e24months suggests that their emergence in
response to D5 represents an adaptive response.
In this chronic bioassay, D5 exposure was associated with a
modest and borderline but statistically signiﬁcant increased inci-
dence of uterine endometrial adenocarcinoma at 160 ppm, the
highest exposure level (See companion manuscript for a discussion
of the statistical approach; Young and Morfeld, 2015). There was noeffect on uterine weight or increased incidence of precursor lesions
such as focal glandular hyperplasia. It has been reported that the
incidence of spontaneous uterine adenocarcinoma in the F344 rat
increases substantially with increasing age, especially ages beyond
24 months (Nyska et al., 1994). The incidence of spontaneous
adenocarcinoma in the rat appears to vary markedly among strain
and sub-strain and appears to reﬂect exposure to ovarian estrogens
without sufﬁcient anti-proliferative exposure to progesterone
(Nagaoka et al., 1990).
The tumors in D5-exposed animals were advanced, raising the
possibility that precursor lesions were obliterated by the spreading
tumors. As discussed in more detail in a companion paper (Klaunig
et al., 2015), the endometrial adenocarcinoma ﬁndings are most
likely consistent with an increase in the time in estrus (due to cycle
alteration) during the ﬁrst year of treatment, with development of
endometrial adenocarcinoma and progression over the second year
of treatment (Group D) or recovery (Group C). Although there was
no reported increase in focal glandular hyperplasia following D5
exposure for 24 months, at least one tumor in the 160 ppm D5
treated group was reported to have glandular hyperplasia associ-
atedwith the tumor. Possible explanations for the lack of associated
precursor lesions include focal precursor lesions that were lost as a
consequence of sectioning or onset of low-grade adenocarcinoma
months prior to the development of persistent diestrus/pseudo-
pregnancy, a state during which precursor lesions may have
regressed. The latter explanation is supported by the observation
from studies in aging F344 rats (Dekant and Klaunig, 2015) that D5
treatment was associated with an increase in estrogen exposure
during the ﬁrst few months of treatment but not thereafter.
Another possibility is that presence of focal glandular hyperplasia
as a precursor lesion is lost as the tumors have progressed to such
an advanced stage that the tumor is now the predominant lesion.
P.A. Jean et al. / Regulatory Toxicology and Pharmacology 74 (2016) S57eS66 S65The adenocarcinomas by this time may have achieved hormone-
independence, preventing their regression in response to proges-
terone dominance.
D5 has been evaluated in a number of studies that cover a wide
range of biological end points. This testing has suggested that D5 is
without signiﬁcant estrogenic/androgenic/progestogenic potential,
and it has not demonstrated mutagenic or genotoxic potential.
Therefore, direct effects on the endometrium by D5 or a genotoxic
mechanism of endometrial carcinogenesis appear unlikely modes
of action to explain the observed increase in endometrial
adenocarcinoma.
5. Conclusion
Inducing an upper respiratory tract response from a chronic
inhalation exposure is perhaps not a surprising outcome. In
contrast an increased incidence of uterine endometrial adenocar-
cinomawas not an outcome anticipated for D5. General descriptive
toxicity testing (acute, sub-acute and sub-chronic) performed prior
to the conduct of the chronic bioassay provided no indication that
the uterus was a potential target organ. This included a demon-
strated lack of mutagenicity/genotoxicity. The target organ and
tumor type speciﬁcity (adenocarcinoma is a common spontaneous
tumor in the aged F344 rat) may suggest the effect is associated
with a treatment related alteration in pituitary control of the
estrous cycle. Potential modes of action responsible for the uterine
tumors and their human relevance is presented in a companion
manuscript (Klaunig et al., 2015).
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